Clinical Trial Update: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adagrasib in KRAS G12C-mutant non-small cell lung cancer patients who are elderly or have poor performance status; the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LUMAKRAS (sotorasib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: NSCLC Stage IV, KRAS P.G12C | Phase 2 | Status: ACTIVE_NOT_RECRUITING